Doses studied, not doses advised
Ipamorelin dosage: what the studies administered, to whom, by which route.
Research-context exposures only — the human PK and trial doses, the rodent regimens, the half-life that governs it all. Nothing here is a protocol.
Read this first
This page reports Ipamorelin dosage only as it appears in published studies — what researchers gave to which species, by which route, for how long. It is not a how-to and contains no recommendation. There is no established human dose, because ipamorelin was never approved and its single human efficacy trial failed [3]. "Half-life" (how fast the body clears half of it) is about 2 hours in people [2], which is why the GH effect is a short pulse, not a steady level. Anything you read online framing a milligram-per-week ipamorelin or CJC-1295/ipamorelin "protocol" is community lore, not clinical guidance — and this site won't restate it as instruction. Below are the actual numbers from the actual papers, in plain third-person.
Doses studied in humans
Two human datasets exist, and they bracket the whole human record. The PK/PD study gave eight men per dose level single IV infusions of 4.21, 14.02, 42.13, 84.27, and 140.45 nmol/kg over 15 minutes; kinetics were dose-proportional with a ~2-hour terminal half-life and a GH pulse peaking ~40 minutes post-dose [2]. The Phase 2 ileus trial administered 0.03 mg/kg IV twice daily for up to 7 days to bowel-resection patients — and missed its primary endpoint (p=0.15) [3]. Both were intravenous and short-duration. There is no published human dosing for the subcutaneous self-injection route that dominates off-label use, and no Phase 3 dose-finding of any kind.
Doses studied in animals
Rodent and ferret studies used a range of routes and exposures. The rat bone-growth study gave 18, 90, and 450 micrograms/day subcutaneously, split three times daily for 15 days, producing dose-dependent longitudinal bone growth [4]. A separate rat bone-mineral study used 0.5 mg/kg/day by continuous subcutaneous osmotic minipump over 12 weeks. Rat postoperative-ileus work used 0.1-1 mg/kg IV repeated four times daily. The 2024 ferret cachexia study used 1-3 mg/kg intraperitoneally [5]. Across the literature, the routes studied are intravenous, subcutaneous, intranasal (~20% bioavailability in rodents), and intraperitoneal; ipamorelin itself is not orally bioavailable (only engineered analogs achieved oral exposure).
The half-life and why it matters
Ipamorelin's terminal half-life is approximately 2 hours in healthy human volunteers (IV), with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg [2]. In rats, plasma clearance runs roughly 5-fold lower than GHRP-6. The practical consequence is that ipamorelin produces a single, discrete GH pulse — peaking near 40 minutes — rather than a sustained elevation. That kinetic profile is exactly what the anti-doping detection windows are built around, and it gets a dedicated treatment on the how long does ipamorelin stay in your system page.
How much cjc-1295 ipamorelin should i take
There is no answer to this that this site will give, because there is no established or studied human dose for the CJC-1295 + ipamorelin combination. The combination has never been tested in a controlled human trial [3], so any milligram figure circulating online is community-derived lore with no peer-reviewed basis. Ipamorelin's only human dosing on record is the IV research exposures above [2][3] — not a take-home protocol. Reporting a number here as guidance would be inventing a recommendation the literature does not support, which this site does not do.
How to reconstitute cjc-1295 ipamorelin 5mg
Reconstitution — dissolving a freeze-dried (lyophilized) peptide powder back into liquid — is a research-handling step, and the literature treats it as such, not as a clinical preparation instruction. Ipamorelin is supplied as a lyophilized powder (free base or acetate salt) and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. Those are general peptide-supply observations [2]. This site does not provide a step-by-step preparation, volume, or dosing method for any combination product — that would cross from describing research into instructing use.